APP and amyloidosis: To test the hypothesis that Kv3.4 downregulation ameliorates dendritic spineloss associated with amyloid pathology, APP/PS1 mice and WT control micewere injected with an AAV containing the sgRNA targetingKv3.4/KCNC4 into neurons of their somatosensorycortex, thereby decreasing Kv3.4 levels in this region.